Bristol Looks To New Abilify Uses But Drops Vinflunine Lead Indication
Executive Summary
Bristol is gearing up for new growth for its atypical antipsychotic Abilify (aripiprazole) with a new direct-to-consumer advertising campaign and a series of expanded indications